MISSISSAUGA, ON, Aug. 8, 2012 /PRNewswire/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical
technologies company, today announced that it is presenting its
latest breakthrough antimicrobial products, including the recently
United States FDA cleared IV Clear™ at the 2012 FIME International
Medical Expo ("FIME") from August 8 to
10 in Miami Beach,
Florida.
As a seminar guest speaker, Dr. Val
DiTizio, Covalon's Chief Scientific Officer will be
discussing why IV Clear is being evaluated by medical institutions
that have adopted programs focused on reducing the instances of
catheter related bloodstream infections. Clinicians have identified
patients who have weak immune systems, sensitive or compromised
skin, or who have long-term catheters as groups who can benefit the
most from IV Clear. Dr. DiTizio's seminar entitled "A Novel
Antimicrobial Clear IV Dressing with Chlorhexidine and Silver" will
be presented at 10:00am in room D238
during the FIME Medical Educational Conference on Thursday August 9th at the Miami Beach Convention Center.
Covalon will also be showcasing its latest wound care products
such as ColActive® Plus Ag, which is cleared for use in the
management of diabetic ulcers and other chronic wounds and
SurgiClear™, its unique antimicrobial transparent silicone adhesive
surgical dressing to the thousands of international and domestic
distributors, group purchasing organizations, hospitals and medical
products dealers attending FIME who are looking for advanced
products to license and distribute.
"IV Clear is truly a new innovation in the fight against
Catheter Related Blood Stream Infections ("CRBSI") and we fully
expect IV Clear to be a strong competitor in the United States and International markets,"
stated Brian Pedlar, Covalon's Chief
Executive Officer. "We are looking forward to establishing new
distribution relationships at FIME with distributors and hospital
buying groups that are interested in sourcing and licensing IV
Clear and other Covalon products."
FIME International Medical Expo, is the largest international
medical trade fair and congress in the
United States for conventional medical distributor networks,
group purchasing organizations, integrated delivery networks,
hospitals, imaging centers, private practice facilities, and home
and durable medical equipment providers seeking the latest medical
products from all over the world.
To learn more about Covalon's products and services, please
visit Covalon at booth #365 in the Miami
Beach Convention Center in Miami
Beach, Florida from August 8 to 10,
2012 or contact Covalon directly:
Brian Pedlar CEO,
Covalon Technologies Ltd. |
Email:
Phone:
Toll free:
Fax:
Web site:
Twitter: |
bpedlar@covalon.com
905.568.8400 x 233
1.877.711.6055
905.568.5200
www.covalon.com
@covalon |
About Covalon
Covalon Technologies Ltd. researches, develops and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.